Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Dow
Johnson and Johnson
AstraZeneca
Merck

Last Updated: January 30, 2023

Vericiguat - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for vericiguat and what is the scope of freedom to operate?

Vericiguat is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vericiguat has two hundred and three patent family members in forty-eight countries.

One supplier is listed for this compound.

Summary for vericiguat
International Patents:203
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 43
Clinical Trials: 12
Patent Applications: 370
What excipients (inactive ingredients) are in vericiguat?vericiguat excipients list
DailyMed Link:vericiguat at DailyMed
Recent Clinical Trials for vericiguat

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BayerPhase 4
Josef StehlikPhase 4
Merck Sharp & Dohme LLCPhase 4

See all vericiguat clinical trials

Pharmacology for vericiguat

US Patents and Regulatory Information for vericiguat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-003 Jan 19, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-003 Jan 19, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-003 Jan 19, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for vericiguat

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Bayer AG Verquvo vericiguat EMEA/H/C/005319
Treatment of symptomatic chronic heart failure
Authorised no no no 2021-07-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for vericiguat

Country Patent Number Title Estimated Expiration
Australia 2012342547 Method for producing substituted 5-fluoro-1H-pyrazolopyridines See Plans and Pricing
South Korea 101943788 See Plans and Pricing
Costa Rica 20210072 PROCEDIMIENTO DE PREPARACIÓN DE 5-FLUORO-1H-PIRAZOLOPIRIDINAS SUSTITUIDAS (METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES) See Plans and Pricing
China 103038232 The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) See Plans and Pricing
Eurasian Patent Organization 201892050 СПОСОБ ПОЛУЧЕНИЯ ЗАМЕЩЕННЫХ 5-ФТОР-1H-ПИРАЗОЛОПИРИДИНОВ See Plans and Pricing
Dominican Republic P2014000112 PROCEDIMIENTO DE PREPARACIÓN DE 5-FLUORO-1H-PIRAZOLOPIRIDINAS SUSTITUIDAS See Plans and Pricing
Peru 20130402 5-FLUORO-1H-PIRAZOLOPIRIDINAS SUSTITUIDAS Y SU USO See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for vericiguat

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2576547 30/2021 Austria See Plans and Pricing PRODUCT NAME: VERICIGUAT SOWIE DESSEN SALZE, SOLVATE UND SOLVATE DER SALZE; REGISTRATION NO/DATE: EU/1/21/1561 (MITTEILUNG) 20210720
2576547 LUC00221 Luxembourg See Plans and Pricing PRODUCT NAME: VERICIGUAT ET SES SELS, SOLVATES ET SOLVATES DES SELS; AUTHORISATION NUMBER AND DATE: EU/1/21/1561 20210720
2576547 PA2021518 Lithuania See Plans and Pricing PRODUCT NAME: VERICIGUATAS IR JO DRUSKOS, SOLVATAI IR DRUSKU SOLVATAI ; REGISTRATION NO/DATE: EU/1/21/1561 20210716
2576547 C02576547/01 Switzerland See Plans and Pricing PRODUCT NAME: VERICIGUAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68001 22.09.2021
2576547 CR 2021 00032 Denmark See Plans and Pricing PRODUCT NAME: VERICIGUAT OG DETS SALTE, SOLVATER OG SOLVATER AF SALTENE; REG. NO/DATE: EU/1/21/1561 20210720
2576547 122021000048 Germany See Plans and Pricing PRODUCT NAME: VERICIGUAT SOWIE DESSEN SALZE, SOLVATE UND SOLVATE DER SALZE; REGISTRATION NO/DATE: EU/1/21/1561 20210716
2576547 C202130044 Spain See Plans and Pricing PRODUCT NAME: VERICIGUAT Y SUS SALES, SOLVATOS Y SOLVATOS DE LAS SALES.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1561; DATE OF AUTHORISATION: 20210716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1561; DATE OF FIRST AUTHORISATION IN EEA: 20210716
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
McKinsey
Colorcon
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.